Literature DB >> 10567003

Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats.

J M Barragán1, J Eng, R Rodríguez, E Blázquez.   

Abstract

This study was designed to determine the contribution of the central nervous system (CNS) to the effects of glucagon-like peptide-1-(7-36) amide (tGLP-1) on arterial blood pressure and heart rate in rats. Accordingly, intracerebroventricular administration of the peptide produced an increase in cardiovascular parameters, which was blocked by previous administration of exendin-(9-39) through the same route, but not when it was intravenously injected. Intravenous administration of tGLP-1 produced a significant increase in arterial blood pressure and heart rate, which was blocked by the previous intracerebroventricular or intravenous administration of exendin-(9-39). Bilateral vagotomy blocked the stimulating effect of intracerebroventricular tGLP-1 administration on arterial blood pressure and heart rate. Also, bilateral vagotomy prevented the blocking effect of intracerebroventricular but not of intravenous exendin-(9-39) on cardiovascular parameters after intravenous administration of tGLP-1. These findings suggest that the action of tGLP-1 on cardiovascular parameters is under a dual control generated in the CNS and in peripheral structures and that the neural information emerging in the brain is transmitted to the periphery through the vagus nerve.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10567003     DOI: 10.1152/ajpendo.1999.277.5.E784

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  49 in total

Review 1.  GLP-1 Agonists and Blood Pressure: A Review of the Evidence.

Authors:  Aditya Goud; Jixin Zhong; Matthew Peters; Robert D Brook; Sanjay Rajagopalan
Journal:  Curr Hypertens Rep       Date:  2016-02       Impact factor: 5.369

Review 2.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

3.  A possible role of GLP-1 in the pathophysiology of early dumping syndrome.

Authors:  Hiroshi Yamamoto; Tsuyoshi Mori; Hiroshi Tsuchihashi; Hiroya Akabori; Hiroyuki Naito; Tohru Tani
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

Review 4.  GLP-1, the gut-brain, and brain-periphery axes.

Authors:  Cendrine Cabou; Rémy Burcelin
Journal:  Rev Diabet Stud       Date:  2011-11-10

Review 5.  Cardiovascular effects of incretin-based therapies.

Authors:  Michael Lehrke; Nikolaus Marx
Journal:  Rev Diabet Stud       Date:  2011-11-10

6.  Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites.

Authors:  Hiroshi Yamamoto; Toshiro Kishi; Charlotte E Lee; Brian J Choi; Hui Fang; Anthony N Hollenberg; Daniel J Drucker; Joel K Elmquist
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

Review 7.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

8.  GLP-1R activation for the treatment of stroke: updating and future perspectives.

Authors:  Vladimer Darsalia; David Nathanson; Thomas Nyström; Thomas Klein; Åke Sjöholm; Cesare Patrone
Journal:  Rev Endocr Metab Disord       Date:  2014-09       Impact factor: 6.514

Review 9.  Leptin and the systems neuroscience of meal size control.

Authors:  Harvey J Grill
Journal:  Front Neuroendocrinol       Date:  2009-10-28       Impact factor: 8.606

10.  GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.

Authors:  Mohammad Hossein Noyan-Ashraf; M Abdul Momen; Kiwon Ban; Al-Muktafi Sadi; Yu-Qing Zhou; Ali M Riazi; Laurie L Baggio; R Mark Henkelman; Mansoor Husain; Daniel J Drucker
Journal:  Diabetes       Date:  2009-01-16       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.